Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients (GIADA)

Engaging the Immune System to Improve the Efficacy of Neoadjuvant Chemo-endocrine Therapy for Premenopausal Luminal B Breast Cancer Patients

Multicentric, phase II neoadjuvant trial in hormone-positive, HER-negative, luminal B, premenopausal breast cancer patients stage II-IIIA. Patients receive as neoadjuvant treatment before surgery: three courses of anthracycline-based chemotherapy followed by exemestane p.o. daily plus nivolumab i.v. 2-weekly for 8 courses. GnRH analogues are started concomitantly with chemotherapy and maintained until the completion of neoadjuvant treatment.

Study Overview

• Status: Completed
• Conditions: Breast Cancer
• Intervention / Treatment: Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Triptorelin; Drug: Exemestane; Drug: Nivolumab

Detailed Description

This is a multicenter, phase II neoadjuvant trial in hormone-sensitive, HER-negative, luminal B, premenopausal breast cancer patients stage II-IIIA.

Patients will undergo a core-biopsy of the primary tumor, for the histological diagnosis and the biological characterization of the tumor.

After confirmation of eligibility and informed consent signature, the patients will start neoadjuvant treatment including:

Epirubicin 90 mg/mq + Cyclophosphamide 600 mg/mq i.v. every 3 weeks for 3 courses, followed by the combination of Nivolumab (240 mg flat dose i.v. each 2 weeks) for 8 courses and exemestane 25 mg (orally, continuous daily dose, to be continued until surgery). Patients will start LHRH analogue (Triptorelin 3.75mg 1 fl i.m. every 28 days) concomitantly to anthracycline-based chemotherapy, to be continued until surgery.

• Study Type: Interventional
• Enrollment (Actual): 43
• Phase: Phase 2

Contacts and Locations

Study Locations

• Italy
  • Padova, Italy, 35128
    • Istituto Oncologico Veneto IRCCS
  • FE
    • Cona, FE, Italy
      • Arcispedale S. Anna
  • PN
    • Aviano, PN, Italy
      • Centro di Riferimento Oncologico di Aviano (CRO)
  • PR
    • Parma, PR, Italy, 43126
      • Azienda Ospedaliera Universitaria di Parma
  • RE
    • Reggio Emilia, RE, Italy
      • Arcispedale S. Maria nuova

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

Patients may be included in the study only if they met all the following criteria

• age >18 yrs
• female patients
• ECOG Performance Status 0-1
• must have signed and dated an IRB/IEC-approved written informed consent form in accordance with regulatory and institutional guidelines before the performance of any protocol-related procedures
• Primary diagnosis of invasive breast cancer, HR positive (ER ≥ 10% and/or PgR ≥10% by IHC) and HER2 negative (IHC 0/1+ and/or FISH/CISH negative) according to local assessment.
• Histologic grade 3 and/or Ki67 >20% according to local assessment.
• Stage II-IIIA
• Eligible for neoadjuvant chemotherapy according to multidisciplinary evaluation.
• Premenopausal status
• Normal organ and marrow function
• Availability of tumor tissue suitable for biological and molecular examination before starting primary treatment
• Ability to understand and willingness to sign a written informed consent document

Exclusion criteria:

Patients will be excluded from the study for any of the following reasons

• Stage IIIB, IIIC, and inflammatory breast cancer
• Stage IV breast cancer
• Prior treatment with chemotherapy, biologic therapy, endocrine therapy or radiotherapy for the treatment of the newly-diagnosed breast cancer.
• Contraindication to anthracycline-based chemotherapy.
• Received any investigational treatment within 4 weeks of study start.
• Any other concurrent chemotherapy, biologic therapy, endocrine therapy or radiotherapy for cancer treatment.
• Known HIV, HBV, HCV infection or any positive tests for HBV and HCV indicating acute or chronic infection.
• Known severe hypersensitivity to any of the study drugs or excipients or known severe hypersensitivity reactions to monoclonal antibodies.
• Major surgical procedure or significant traumatic injury within 28 days prior to treatment initiation or anticipation of need for major surgery during the course of study treatment.
• History of allogenic organ transplantation
• Clinically significant (that is, active) cardiovascular disease: cerebral vascular accident /stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥ II), or serious uncontrolled cardiac arrhythmia requiring medication.
• Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of treatment initiation.
• Subjects with active, known or suspected autoimmune disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
• Any other serious or uncontrolled medical disorder, active infection, physical exam finding, laboratory finding, altered mental status, or psychiatric condition that, in the opinion of the investigator, would limit a subject's ability to comply with the study requirements, substantially increase risk to the subject, or impact the interpretability of study results.
• Prisoners or subjects who are involuntarily incarcerated
• Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
• Lack of physical integrity of the upper gastrointestinal tract, clinically significant malabsorption syndrome, or inability to take oral medication.
• Psychiatric illness/social situations that would limit compliance with study requirements
• Subjects assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
• Current pregnancy and/or lactation.
• Refusal to adopt adequate (highly effective) contraception methods.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

EXPERIMENTAL: Arm 1; Epirubicin 90 mg/mq + Cyclophosphamide 600 mg/mq i.v. every 3 weeks for 3 courses, followed by Nivolumab (240 mg flat dose i.v. each 2 weeks) for 8 courses plus exemestane 25 mg (orally, continuous daily dose, to be continued until surgery). LHRH analogue (Triptorelin 3.75mg 1 fl i.m. every 28 days) started concomitantly to anthracycline based chemotherapy, to be continued until surgery.

Drug: Epirubicin; Epirubicin 90 mg/mq i.v. every 3 weeks for three cycles; Drug: Cyclophosphamide; Cyclophosphamid 600 mg/mq i.v. every 3 weeks for three cycles; Drug: Triptorelin; Triptorelin 3.75 mg i.m. every 4 weeks until surgery; Drug: Exemestane; Exemestane 25 mg oral continuous daily dose until surgery; Drug: Nivolumab; Nivolumab 240 mg flat dose i.v. every two weeks for 8 cycles; Other Names: BMS-936558

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
pathological complete response (pCR)	ypT0ypN0	up to 7 months from enrolment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
clinical objective response	cOR	up to 6 months from enrolment
molecular response	Ki67	up to 7 months from enrolment
Breast conserving surgery	Surgery type	up to 7 months from enrolment
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	Adverse Events	up to 100 days from last nivolumab dose
Correlative biomarkers	correlation between different biomarkers expression at baseline and pathological response	Tumor samples will be collected at baseline, at 14 days after completion of anthracycline-based chemotherapy (about 7 weeks after first dose of Epirubicin), at surgery (about 30 weeks after first dose of Epirubicin)

Collaborators and Investigators

• Sponsor: Istituto Oncologico Veneto IRCCS
• Collaborators: University of Padova
• Investigators: Principal Investigator: Pierfranco Conte, MD, University of Padova

Publications and helpful links

General Publications

• Dieci MV, Guarneri V, Tosi A, Bisagni G, Musolino A, Spazzapan S, Moretti G, Vernaci GM, Griguolo G, Giarratano T, Urso L, Schiavi F, Pinato C, Magni G, Lo Mele M, De Salvo GL, Rosato A, Conte P. Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. Clin Cancer Res. 2022 Jan 15;28(2):308-317. doi: 10.1158/1078-0432.CCR-21-2260. Epub 2021 Oct 19.

Study record dates

Study Major Dates

• Study Start (ACTUAL): October 5, 2017
• Primary Completion (ACTUAL): May 25, 2020
• Study Completion (ACTUAL): May 25, 2020

Study Registration Dates

• First Submitted: February 23, 2018
• First Submitted That Met QC Criteria: December 2, 2020
• First Posted (ACTUAL): December 9, 2020

Study Record Updates

• Last Update Posted (ACTUAL): December 9, 2020
• Last Update Submitted That Met QC Criteria: December 2, 2020
• Last Verified: December 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Antineoplastic Agents, Immunological; Antibiotics, Antineoplastic; Hormone Antagonists; Immune Checkpoint Inhibitors; Aromatase Inhibitors; Steroid Synthesis Inhibitors; Estrogen Antagonists; Contraceptive Agents, Hormonal; Contraceptive Agents; Reproductive Control Agents; Contraceptive Agents, Female; Luteolytic Agents; Cyclophosphamide; Epirubicin; Nivolumab; Triptorelin Pamoate; Exemestane
• Other Study ID Numbers: GIADA Trial; 2016-004665-10 (EUDRACT_NUMBER)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No